![Jarrod Longcor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jarrod Longcor
Geschäftsführer bei
CELLECTAR BIOSCIENCES, INC.
Vermögen: 35 495 $ am 30.06.2026
Profil
Mr. Jarrod Longcor is a Chief Operating Officer at Cellectar Biosciences, Inc. Mr. Longcor was previously employed as a Chief Business Officer by Avillion LLP, a Vice President-Corporate Development by Melinta Therapeutics, Inc. /Old/, a Director-Business Development by MaxCyte, Inc., and a Senior Director-Business Development by Middlebrook Pharmaceuticals, Inc. He received his undergraduate degree from Dickinson College, a graduate degree from Boston University School of Medicine and an MBA from Erivan K.
Haub School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.07.2026 | 12.768 ( 0,48 % ) | 35 495 $ | 30.06.2026 |
Aktive Positionen von Jarrod Longcor
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Geschäftsführer | 23.02.2022 |
Ehemalige bekannte Positionen von Jarrod Longcor
| Unternehmen | Position | Ende |
|---|---|---|
Avillion LLP
 Avillion LLP BiotechnologyHealth Technology Engages in clinical development of therapeutics | Corporate Officer/Principal | 01.07.2016 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for the treatment of life-threatening infections | Corporate Officer/Principal | 01.09.2013 |
| MAXCYTE, INC. | Corporate Officer/Principal | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pulsatile drug products | Corporate Officer/Principal | - |
Ausbildung von Jarrod Longcor
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
40
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pulsatile drug products | Health Technology |
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
Dickinson College
 Dickinson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for the treatment of life-threatening infections | Health Technology |
Avillion LLP
Avillion LLP BiotechnologyHealth Technology Engages in clinical development of therapeutics | Health Technology |
Cellectar Biosciences, Inc.
 Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
Boston University School of Medicine
 Boston University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Erivan K. Haub School of Business
 Erivan K. Haub School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
